The Arizona Minority CCOP is a consortium between Maricopa Medical Center and Phoenix Indian Medical Center. St. Luke's Medical Center will be included as an affiliate. Maricopa Medical Center, the county hospital of Phoenix, deals with a large Hispanic minority population. Phoenix Indian Medical Center and the Phoenix Indian area health service extend from the small Cocopah tribe in Southwestern Arizona to the widely dispersed Paiute Indians in Nevada and Utah. This large area includes more than 100,000 people who receive health services from the Phoenix area Indian health service. St. Luke's Medical Center has one of the major Arizona Medicaid (AHCCCS) programs which has a large Hispanic patient population. This application represents a desire to bring the benefits of National Cancer Institute programs to an under-served Hispanic population in Phoenix and the Native American population served by the Phoenix area Indian health service. We will associate with the North Central Cancer Treatment Group because we feel their protocols fit our patient population the best. Our secondary research base will be the Eastern Cooperation Oncology Group. Mayo Clinic Comprehensive Cancer Center will be a tertiary research base for minority cancer control studies. Our cancer control minority program was fostered by the Arizona Disease Control Research Commission's $75,000 grant for Dr. Lobell to study barriers to cancer prevention, diagnosis and treatment in Hispanics. The Phase I study has been completed and a Phase II implementation study using """"""""promotora"""""""" is already underway in the greater Phoenix community in conjunction with a similar program at Arizona State University. To enroll Native Americans on National Cancer Institute treatment and control protocols we propose a decentralized program for Native American patient accrual. This program will be performed in coordination with the Phoenix area Indian health service stations by establishing a close working relationship between the physicians and nurses at these stations and the professional staff at Maricopa Medical Center and Phoenix Indian Medical Center. We feel the required patient accrual to cancer treatment and control protocols can be obtained if the necessary support is provided. We are committed to the formation of new cancer control programs that are culturally sensitive and will address the pressing needs of cancer prevention and detection in the Native American and Hispanic populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA063826-02
Application #
2105929
Study Section
Special Emphasis Panel (SRC (86))
Project Start
1994-09-30
Project End
1997-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Maricopa Medical Center
Department
Type
DUNS #
City
Phoenix
State
AZ
Country
United States
Zip Code
85008
Bolton, John S; O'Connell, Michael J; Mahoney, Michelle R et al. (2012) Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer 11:31-7
Halyard, Michele Y; Pisansky, Thomas M; Dueck, Amylou C et al. (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 27:2638-44
Racila, Emilian; Link, Brian K; Weng, Wen-Kai et al. (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697-703
Ansell, Stephen M; Inwards, David J; Rowland Jr, Kendrith M et al. (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 113:508-14
Croghan, Ivana T; Hurt, Richard D; Dakhil, Shaker R et al. (2007) Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 82:186-95
Jatoi, Aminah; Burch, Patrick; Hillman, David et al. (2007) A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology 69:289-94
Marshall, Nicole E; Ballman, Karla V; Michalak, John C et al. (2006) Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. J Neurooncol 77:315-20
Buckner, Jan C; Ballman, Karla V; Michalak, John C et al. (2006) Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group J Clin Oncol 24:3871-9
Moreno-Aspitia, Alvaro; Colon-Otero, Gerardo; Hoering, Antje et al. (2006) Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer 107:767-72
Jatoi, A; Murphy, B R; Foster, N R et al. (2006) Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:29-34

Showing the most recent 10 out of 37 publications